Ingen internetforbindelse — viser den gemte version af siden.

10x Genomics, Inc…

USUSD
← Til Screeneren

10x Genomics, Inc. (LSE:0A88) — Biotechnology: Laboratory Analytical Instruments. Antal børser, hvor selskabets aktier handles: 2. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
10xgenomics.com
Sektor
Industrials · Biotechnology: Laboratory Analytical Instruments
Hovedkontor
Pleasanton, United States
Administrerende Direktør
Serge Saxonov
Ansatte
1 178
Grundlagt
2012
Udestående Aktier
120.21 mio.
Free Float
118.19 mio.
Markedsværdi
11.53 mia. USD
Insidere
1.46%
Institutionelle Investorer
120.2%
Branche (SIC)
Laboratory Analytical Instruments
Juridisk Form
XTIQ
ISIN
US88025U1097
LEI
5493003Z6741WNLG7H43
FCF
121 mio. USD
Gæld
0 USD
nettokasse
Indtjening og FCF — for de 12 måneder frem til 30.06.2026 (virksomhedens seneste rapport).
NAV
6.87 USD · P/NAV 12.9
Balancedato30.06.2026
Aktiver1.03 mia. USD
− Forpligtelser205 mio. USD
= NAV (aktiekapital i selskabets aktionærer)826 mio. USD
− Goodwill6.92 mio. USD
− Immaterielle Aktiver61.2 mio. USD
= Materiel NAV757 mio. USD
Aktier120 212 296
NAV pr. Aktie6.87 USD
Håndgribelig NAV pr. Aktie6.30 USD
Aktiekurs (0A88)88.3100 USD
P/NAV12.86
NAV-Historie
BalancedatoNAVNAV pr. Aktie
30.06.2026826 mio. USD6.87 USD
31.03.2026814 mio. USD6.77 USD
31.12.2025796 mio. USD6.24 USD
30.09.2025785 mio. USD6.53 USD
30.06.2025773 mio. USD6.43 USD
31.03.2025707 mio. USD5.88 USD
31.12.2024710 mio. USD5.81 USD
30.09.2024723 mio. USD6.01 USD
Beskrivelse

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

annonce

Børser og Tickere

BørsTickerValutaPrisType
US USA StocksTXG primærUSD69.86 -3.49%almindelige aktier
LSE London Stock Exchange0A88 IOBUSD88.31 +0.00%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdagHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Største Ejere

EjerAndelAktierRapportdato
FMR, LLC14.67%17.63 mio.2026-06-30
Blackrock Inc.8.99%10.8 mio.2026-06-30
ARK Investment Managemen…8.32%10 mio.2026-06-30
Vanguard Portfolio Manag…5.81%6.98 mio.2026-06-30
Quantinno Capital Manage…4.55%5.47 mio.2026-06-30
Vanguard Capital Managem…4.23%5.08 mio.2026-06-30
Price (T.Rowe) Associate…3.78%4.54 mio.2026-06-30
Sumitomo Mitsui Trust Gr…3.49%4.19 mio.2026-06-30
Amova Asset Management A…3.49%4.19 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.94%3.53 mio.2026-06-30
Morgan Stanley2.79%3.35 mio.2026-06-30
iShares Trust-iShares Ru…2.53%3.04 mio.2026-07-31
ARK ETF Trust-ARK Genomi…2.53%3.04 mio.2026-08-31
ARK ETF Trust-ARK Innova…2.5%3.01 mio.2026-08-31
VANGUARD INDEX FUNDS-Van…2.12%2.55 mio.2026-06-30
Fidelity Select PORT.s-S…1.66%2 mio.2026-07-31
Fidelity Rutland Square…1.37%1.65 mio.2026-07-31
Fidelity Select Portfoli…1.34%1.61 mio.2026-07-31
VANGUARD INDEX FUNDS-Van…1.22%1.47 mio.2026-06-30
T. Rowe Price New Horizo…1.21%1.46 mio.2026-06-30
SAXONOV SERGE WILSON (Ch…≈1.11%1.34 mio.2026-09-22
HINDSON BENJAMIN J (Pres…≈0.41%488 1822026-08-24
STUELPNAGEL JOHN R (Dire…≈0.27%328 4362026-09-03
TAICH ADAM (Chief Financ…≈0.26%316 3442026-09-09
MATEO ALAN V. (Director)≈0.07%85 8772026-06-04
KOSARAJU SRIDHAR (Direct…≈0.06%68 2782026-06-04
POPOVITS KIMBERLY J (Dir…≈0.03%37 4452026-06-04
TEICHMANN SARAH A. (Dire…≈0.02%28 0582026-08-14
SULIMAN SHEHNAAZ (Direct…≈0.02%23 7922026-09-22